As of February 23, 2021, TransEnterix has been renamed Asensus Surgical, Inc.
Along with the name change, the ticker symbol will change to “ASXC” upon the open of trading on Friday, March 5, 2021. Up until that point, the stock will continue to trade under the company name TransEnterix and ticker symbol TRXC.
If you are an existing investor, your ownership will not be impacted. Beginning on March 5, 2021, your holdings will automatically be renamed as Asensus Surgical, ticker symbol ASXC. Up until that point, the stock will continue to show up as TransEnterix and ticker symbol TRXC.
================================================================================ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------------- FORM 8-K CURRENT REPORT -------------------- Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 2, 1997 CELLULAR TECHNICAL SERVICES COMPANY, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-19437 11-2962080 (State or Other Jurisdiction (Commission File Number) (I.R.S. Employer of Incorporation) Identification No.) 2401 Fourth Avenue Seattle, Washington 98121 (Address of Principal Executive Offices) (Zip Code) (206) 443-6400 (Registrant's telephone number, including area code) ================================================================================
This Current Report on Form 8-K is filed by Cellular Technical Services Company, Inc., a Delaware corporation (the "Company"), in connection with the matters described herein. ITEM 5. OTHER EVENTS In an action brought against the Company by Reon International Corp. and Reon Corp. in the Superior Court of King County, Washington, the plaintiffs allege breach of contract, misappropriation of trade secrets, and breach of other obligations by the Company. The action was filed in late July 1996 and, since that time, a significant number of the plaintiffs' initial claims have been dismissed. The plaintiffs have amended their complaint three times, most recently in January 1997, and now allege that certain transactions between the parties constitute a joint venture partnership. The plaintiffs seek dissolution of the alleged joint venture partnership, damages in excess of $10 million, and other relief. The Company has formally denied all of the plaintiffs' claims and is vigorously defending this action. It is the opinion of the Company's management that this action is without merit and will be resolved without a material adverse effect on the Company. -2- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 27, 1997 CELLULAR TECHNICAL SERVICES, COMPANY, INC. By: /s/ Michael E. McConnell ------------------------------- Michael E. McConnell, Chief Financial Officer -3-